双歧三联活菌制剂治疗新生儿高胆红素血症的疗效评价

The valuation of Bifid Triple Viable in treatment of neonatal hyperbilirubinemia

目的:观察双歧三联活菌制剂在治疗新生儿高胆红素血症中的临床疗效。方法:将50例新生儿高胆红素血症患儿随机分为治疗组和对照组各25例。对照组进行常规治疗,治疗组在常规治疗的基础上,加服双歧三联活菌制剂,通过检测血清胆红素浓度评价其疗效。结果:治疗组和对照组总有效率分别为100、84.0,两组比较差异有统计学意义(χ2=4.35,P<0.05);治疗后血清胆红素值治疗组为(45.61±17.32)μmol/L,对照组为(89.38±49.98)μmol/L,两组比较差异有统计学意义(t=4.14,P<0.05);胆红素开始下降时间治疗组为(2.3±0.6)d,对照组为(3.8±0.3)d,两组比较差异有统计学意义(t=11.18,P<0.05);黄疸消退时间治疗组为(4.1±2.4)d,对照组为(7.1±3.2)d,两组比较差异有统计学意义(t=3.75,P<0.01)。结论:双歧三联活菌制剂辅助治疗新生儿高胆红素血症疗效好,可迅速降低血清胆红素水平,缩短治疗时间,值得临床推广。

Objective ：To observe the effect of Bifid Triple Viable in treatment of neonatal hyperbilirubinemia. Methods： 50 patients with neonatal hyperbilirubinemia were stochastically divided into 2 groups including control group treated with routine method and treatment group treated with routine method and Bifid Triple Viable. Results： There was significant difference in total effective rate between the treatment group （ 100% ） and the control group （84.0%） in post-treatment （X2 = 4.35, P 〈 0.05）. There was significant difference in serum bilirubin between the two groups in post-treatment （ t = 4.14, P 〈 0.05 ）. And there was significant difference in time of bilirubin＇ s reducing in plasma and jaundice＇ s elapsing on skin between them in post-treatment （t = 11. 18, P 〈0.05, t=3.75, P 〈0. 01）. Conclusions：Bifid Triple Viable has good effects on neonatal hyperbilirubinemia and reduces bilirubin in serum with no side-effect so it was worth wide spreading in clinical practice.